Replies to post #210307 on Biotech Values

[DewDiligence]

JUNO has a small piece of [NVS’ CTL019] action through settlement of patent litigation.

The operative word is small. From what has been disclosed about the patent settlement (#msg-112436395), it doesn’t sound like much. JUNO’s share of the royalty NVS pays to UofP can probably be ignored since it’s a second-order derivative tantamount to round-off error. Moreover, JUNO has to share its overall CTL019 take with St Jude Hospital.